Summary of Use during Lactation

No information is available on the clinical use of luspatercept during breastfeeding. Because luspatercept is a large protein molecule with a molecular weight of 76,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Until more data become available, the manufacturer recommends that breastfeeding be discontinued during luspatercept therapy and for 3 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Luspatercept

CAS Registry Number

1373715-00-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Hematinics

Hematopoietic Cell Growth Factors